Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1997;29:1173-1177

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Petersen, J. S.
Right arrow Articles by Varner, K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petersen, J. S.
Right arrow Articles by Varner, K. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*METFORMIN HYDROCHLORIDE

(Hypertension. 1997;29:1173-1177.)
© 1997 American Heart Association, Inc.


Articles

Metformin Inhibits Ganglionic Neurotransmission in Renal Nerves

Jørgen S. Petersen; Wen Liu; Daniel R. Kapusta; ; Kurt J. Varner

From the Department of Pharmacology, The Panum Institute, University of Copenhagen, Denmark (J.S.P.), and Department of Pharmacology, Louisiana State University Medical Center, New Orleans.

Correspondence to Jørgen Søberg Petersen, MD, PhD, Department of Pharmacology, The Panum Institute, Bldg 18.6, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark. E-mail fijsp{at}farmakol.ku.dk

Abstract Intravenous administration of the antihyperglycemic agent metformin decreases arterial pressure and sympathetic nerve activity (SNA). To test the hypothesis that metformin inhibits SNA by interrupting ganglionic neurotransmission, we compared the actions of intravenous administration of metformin and the ganglionic blocker trimethaphan on postganglionic renal and preganglionic adrenal sympathetic nerves in pentobarbital-anesthetized male Sprague-Dawley rats. Intravenous metformin elicited dose-dependent decreases in postganglionic renal SNA (1 mg/kg: 0±0%; 10 mg/kg: -20±4%; 100 mg/kg: -92±3%; n=7). Conversely, only the maximal dose of metformin affected preganglionic adrenal SNA (100 mg/kg: {Delta}adrenal SNA=-14±6%; n=8). Ganglionic blockade with intravenous trimethaphan (5 mg/kg) produced a differential sympathoinhibitory response similar to the response observed after high-dose metformin ({Delta}renal SNA=-100±3%; {Delta}adrenal SNA=-17±7%; P<.001). Preganglionic renal neurons were electrically stimulated in the spinal cord, before and during the peak of the sympathoinhibitory response to intravenous metformin, and the magnitude of the stimulus-evoked increases in postganglionic renal SNA were compared. Metformin dose-dependently attenuated the magnitude of the increase in postganglionic renal SNA elicited by stimulation of the spinal cord (30 mg/kg: -23±8%; 90 mg/kg: -65±11%; 270 mg/kg: -91±8%; n=6 per dose). We conclude that high-dose intravenous metformin interrupts ganglionic neurotransmission in renal nerves.


Key Words: metformin • sympathetic nerve activity • neurotransmission • diabetes mellitus




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
B. Fruehwald-Schultes, W. Kern, K. M. Oltmanns, S. Sopke, B. Toschek, J. Born, H. L. Fehm, and A. Peters
Metformin Does Not Adversely Affect Hormonal and Symptomatic Responses to Recurrent Hypoglycemia
J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4187 - 4192.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. D. Peuler
Opposing adrenergic actions of intravenous metformin on arterial pressure in female spontaneously hypertensive rats
Cardiovasc Res, July 1, 1999; 43(1): 237 - 247.
[Abstract] [Full Text] [PDF]